DARICON Drug Patent Profile
✉ Email this page to a colleague
When do Daricon patents expire, and what generic alternatives are available?
Daricon is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in DARICON is oxyphencyclimine hydrochloride. Additional details are available on the oxyphencyclimine hydrochloride profile page.
Summary for DARICON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 46 |
Patent Applications: | 96 |
DailyMed Link: | DARICON at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for DARICON
US Patents and Regulatory Information for DARICON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | DARICON | oxyphencyclimine hydrochloride | TABLET;ORAL | 011612-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |